BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to conduct a phase 2 COVID-19 clinical trial using its repurposed drug NP-120 (Ifenprodil). Based on the feedback, the Company plan

Mettler-Toledo International Inc. (NYSE: MTD), a leading global supplier of precision instruments and services, announced today that due to the negative impact of the global spread of the COVID-19 pandemic, it is withdrawing 2020 annual guidance, which was provided on February 6, 2020 . For the first quarter ended March 31, 20

EmpiraMed, a leader in the field of virtual registries for Real World Evidence, announced that it is collaborating with LUNGevity Foundation, the nation’s pre-eminent lung cancer non-profit, on a global study, Project PEER, to gather patient reported outcomes from lung cancer patients and their caregivers in a real-world setting.

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced that the U.S. Food & Drug Administration (“FDA”) has accepted its supplemental new drug application (“sNDA”) for Purified Cortrophin® Gel (Repository Corticotrop

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that its joint venture, ImmuneCyte Life Sciences, Inc., has completed the acquisition of worldwide intellectual property for developing fully human antibody therapeu

vybe urgent care, with 11 centers in the greater Philadelphia market, is making drive-up COVID-19 testing easy for patients.

Providers can remotely order valuable laboratory testing as part of their telehealth programs - Patients can now submit samples without leaving the comfort and safety of their homes.

ProLynx LLC today announced that the first patient was treated with its PLX038 in a Phase 1B clinical trial for small-cell lung cancer at the National Cancer Institute (NCI). The trial combines its long-acting PEGylated SN-38, PLX038, with the Clovis Oncology PARP inhibitor, rucaparib. In preclinical studies, the PEG~SN-38 nanomolecule accumulates and is retained for long periods in tumors where it slowly releases the DNA-damaging agent SN-38.

Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today provided an update on actions the Company is taking in response to the COVID-19 pandemic.

WAT Medical Enterprise Ltd. conducted an investigation on solutions to cyber sickness (a form of nausea-induced vomiting). WAT Medical team has been studying has achieved positive results with the use of EmeTerm.